CORRECTION article

Front. Immunol., 13 June 2025

Sec. Multiple Sclerosis and Neuroimmunology

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1609054

Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series

  • 1. Regina Berkovich MD, PhD Inc (MS Center and Research Institute), West Hollywood, CA, United States

  • 2. Department of Neurology, Minnesota Center for Multiple Sclerosis, Plymouth, MN, United States

  • 3. Department of Neurology, MS Center of Greater Washington, Vienna, VA, United States

  • 4. Department of Neurology, Rocky Mountain MS Clinic, Salt Lake City, UT, United States

  • 5. Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany

  • 6. Department of Neurology, The Elliot Lewis Center, Wellesley, MA, United States

  • 7. Atlantic Medical Group Multiple Sclerosis Comprehensive Care Center, Bridgewater, NJ, United States

Article metrics

View details

1,3k

Views

317

Downloads

In the published article, there was an error in affiliation 1. Instead of “Berkovich MS Center and Research Institute, West Hollywood, CA, United States,” it should be “Regina Berkovich MD, PhD Inc (MS Center and Research Institute), West Hollywood, CA, United States.”

Also, there was an error in Figure 1, Figure 3, and Figure 4 as published. The y-axis titles of these figures contained a typo listing the unit of measure as “cells/¼ L”; the correct unit of measure is “cells/µL.” The corrected Figure 1, Figure 3, and Figure 4 and their captions appear below.

Figure 1

Figure 3

Figure 4

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

anti-CD20, B-cell depletion, disability, magnetic resonance imaging, multiple sclerosis, ocrelizumab, rituximab, ublituximab

Citation

Berkovich R, Calkwood J, Crayton H, Erwin A, Faissner S, Gold R, Katz J and Leekoff M (2025) Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series. Front. Immunol. 16:1609054. doi: 10.3389/fimmu.2025.1609054

Received

09 April 2025

Accepted

26 May 2025

Published

13 June 2025

Volume

16 - 2025

Edited and reviewed by

Anne Haney Cross, Washington University in St. Louis, United States

Updates

Copyright

*Correspondence: Regina Berkovich,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics